These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34714078)

  • 1. Discovery of
    Reutershan MH; Machacek MR; Altman MD; Bogen S; Cai M; Cammarano C; Chen D; Christopher M; Cryan J; Daublain P; Fradera X; Geda P; Goldenblatt P; Hill AD; Kemper RA; Kutilek V; Li C; Martinez M; McCoy M; Nair L; Pan W; Thompson CF; Scapin G; Shizuka M; Spatz ML; Steinhuebel D; Sun B; Voss ME; Wang X; Yang L; Yeh TC; Dussault I; Marshall CG; Trotter BW
    J Med Chem; 2021 Nov; 64(21):16213-16241. PubMed ID: 34714078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phe19 modification of HDM2-p53 PPI inhibitors to alleviate CYP3A4 metabolism/mechanism-based inhibition liability.
    Tian Y; Lahue BR; Ma Y; Nair LG; Pan W; Doll RJ; Guzi T; Ma Y; Wang Y; Bogen SL
    Bioorg Med Chem Lett; 2022 Apr; 61():128625. PubMed ID: 35158044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design.
    Parks DJ; LaFrance LV; Calvo RR; Milkiewicz KL; Marugán JJ; Raboisson P; Schubert C; Koblish HK; Zhao S; Franks CF; Lattanze J; Carver TE; Cummings MD; Maguire D; Grasberger BL; Maroney AC; Lu T
    Bioorg Med Chem Lett; 2006 Jun; 16(12):3310-4. PubMed ID: 16600594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Miniature protein inhibitors of the p53-hDM2 interaction.
    Kritzer JA; Zutshi R; Cheah M; Ran FA; Webman R; Wongjirad TM; Schepartz A
    Chembiochem; 2006 Jan; 7(1):29-31. PubMed ID: 16397877
    [No Abstract]   [Full Text] [Related]  

  • 5. Small molecule inhibitors of the p53-MDM2.
    Hu CQ; Hu YZ
    Curr Med Chem; 2008; 15(17):1720-30. PubMed ID: 18673221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.
    Gonzalez AZ; Li Z; Beck HP; Canon J; Chen A; Chow D; Duquette J; Eksterowicz J; Fox BM; Fu J; Huang X; Houze J; Jin L; Li Y; Ling Y; Lo MC; Long AM; McGee LR; McIntosh J; Oliner JD; Osgood T; Rew Y; Saiki AY; Shaffer P; Wortman S; Yakowec P; Yan X; Ye Q; Yu D; Zhao X; Zhou J; Olson SH; Sun D; Medina JC
    J Med Chem; 2014 Apr; 57(7):2963-88. PubMed ID: 24601644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probing the structural requirements of peptoids that inhibit HDM2-p53 interactions.
    Hara T; Durell SR; Myers MC; Appella DH
    J Am Chem Soc; 2006 Feb; 128(6):1995-2004. PubMed ID: 16464101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligobenzamide proteomimetic inhibitors of the p53-hDM2 protein-protein interaction.
    Plante JP; Burnley T; Malkova B; Webb ME; Warriner SL; Edwards TA; Wilson AJ
    Chem Commun (Camb); 2009 Sep; (34):5091-3. PubMed ID: 20448956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy.
    Liao G; Yang D; Ma L; Li W; Hu L; Zeng L; Wu P; Duan L; Liu Z
    Eur J Med Chem; 2018 Nov; 159():1-9. PubMed ID: 30253242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
    Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationship study of 4-substituted piperidines at Leu26 moiety of novel p53-hDM2 inhibitors.
    Tian Y; Ma Y; Gibeau CR; Lahue BR; Shipps GW; Strickland C; Bogen SL
    Bioorg Med Chem Lett; 2016 Jun; 26(11):2735-8. PubMed ID: 27080185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Core modification of substituted piperidines as novel inhibitors of HDM2-p53 protein-protein interaction.
    Pan W; Lahue BR; Ma Y; Nair LG; Shipps GW; Wang Y; Doll R; Bogen SL
    Bioorg Med Chem Lett; 2014 Apr; 24(8):1983-6. PubMed ID: 24656661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substituted 1,4-benzodiazepine-2,5-diones as alpha-helix mimetic antagonists of the HDM2-p53 protein-protein interaction.
    Cummings MD; Schubert C; Parks DJ; Calvo RR; LaFrance LV; Lattanze J; Milkiewicz KL; Lu T
    Chem Biol Drug Des; 2006 Mar; 67(3):201-5. PubMed ID: 16611213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
    Zhuang C; Miao Z; Zhu L; Dong G; Guo Z; Wang S; Zhang Y; Wu Y; Yao J; Sheng C; Zhang W
    J Med Chem; 2012 Nov; 55(22):9630-42. PubMed ID: 23046248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode.
    Gessier F; Kallen J; Jacoby E; Chène P; Stachyra-Valat T; Ruetz S; Jeay S; Holzer P; Masuya K; Furet P
    Bioorg Med Chem Lett; 2015 Sep; 25(17):3621-5. PubMed ID: 26141769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization beyond AMG 232: discovery and SAR of sulfonamides on a piperidinone scaffold as potent inhibitors of the MDM2-p53 protein-protein interaction.
    Wang Y; Zhu J; Liu JJ; Chen X; Mihalic J; Deignan J; Yu M; Sun D; Kayser F; McGee LR; Lo MC; Chen A; Zhou J; Ye Q; Huang X; Long AM; Yakowec P; Oliner JD; Olson SH; Medina JC
    Bioorg Med Chem Lett; 2014 Aug; 24(16):3782-5. PubMed ID: 25042256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of the p53/hdm2 protein-protein interaction-path to the clinic.
    Carry JC; Garcia-Echeverria C
    Bioorg Med Chem Lett; 2013 May; 23(9):2480-5. PubMed ID: 23541651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced Suppression of a Protein-Protein Interaction in Cells Using Small-Molecule Covalent Inhibitors Based on an
    Ueda T; Tamura T; Kawano M; Shiono K; Hobor F; Wilson AJ; Hamachi I
    J Am Chem Soc; 2021 Mar; 143(12):4766-4774. PubMed ID: 33733756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction.
    Vaupel A; Bold G; De Pover A; Stachyra-Valat T; Lisztwan JH; Kallen J; Masuya K; Furet P
    Bioorg Med Chem Lett; 2014 May; 24(9):2110-4. PubMed ID: 24704029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer.
    Patel S; Player MR
    Expert Opin Investig Drugs; 2008 Dec; 17(12):1865-82. PubMed ID: 19012502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.